 |
 |
| |
VIZYX.dlm
– The ICM Solution
The ICM Corporation solution, VIZYX.dlm™
is a patented, integrated solution for automating all
departments across a Life Sciences organization, including
Documentation, Quality, Regulatory Medical and Clinical.
VIZYX.dlm helps you to achieve dramatic gains in capacity
and worker productivity while at the same time reducing
the cost and complexities associated with regulatory
compliance.
Why is DLM Patented?
VIZYX.dlm is the industry's first holistic
solution designed to manage the complete life cycle
of the development and management of a drug. VIZYX Drug
Life-cycle Management begins with research and development,
testing and FDA approval management, continues through
manufacture, marketing and stability testing, and finally
ends when the drug batch expires and has to be withdrawn
or the drug is withdrawn from the market.
Drug Life-cycle Management
DLM is a combination of software and business
process automation. When combined, they provide a platform
for the development of scientific/technical, regulatory,
and marketing strategies that are designed to enhance
the value and manage the life cycle of pharmaceutical
drugs and devices.
At its core DLM is an integrated platform with modules
designed and developed to remove the difficulties associated
with automating the complex business processes within
Life Sciences companies. By integrating the modules listed
below, the company benefits from seamless access to information
and continually monitored risk management. For example,
the centralized time/date server ensures all matters with
critical time elements are automated and that users are
apprised of these events and their criticality. Supervisors
are notified of any potential delays in responding to
events.
Cost Savings Through Innovative Pricing and
Validation
The VIZYX.dlm v6.7™ solution is provided
with the requisite IQ/OQ/PQ validation scripts to reduce
the traditional costs associated with validation and
validation consultants. VIZYX.dlm allows the client
to retain control of their environment and data (as
required by the FDA) and thus avoiding the large upfront
expenses associated with traditional software silos,
such as infrastructure expenses, the deployment, validation
and maintenance of the environment, and support of the
users.
The ICM solution requires little upfront capital investment
thanks to the innovative Subscription Pricing,
whereby the client pays on a monthly subscription basis
only for the functionality used. For example, Subscription
Pricing provides for an initial implementation
fee, followed by a monthly subscription payment that
increases only as optional functionality is added to
the environment. Payments include all software, maintenance,
validation, and deployment costs. In addition, once
the subscription agreement is signed, a clear road map
of feature upgrades is given laying out when feature
upgrades will occur, allowing the company to budget
accordingly. |
|
